{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T19:53:07Z","timestamp":1773258787150,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,8,29]],"date-time":"2017-08-29T00:00:00Z","timestamp":1503964800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13045-017-0520-1","type":"journal-article","created":{"date-parts":[[2017,8,29]],"date-time":"2017-08-29T12:44:52Z","timestamp":1504010692000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test"],"prefix":"10.1186","volume":"10","author":[{"given":"Eddy C.","family":"Hsueh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R.","family":"DeBloom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey J.","family":"Sussman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle R.","family":"Covington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brooke","family":"Middlebrook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clare","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert W.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Craig L.","family":"Slingluff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly M.","family":"McMasters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,29]]},"reference":[{"key":"520_CR1","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199\u2013206.","journal-title":"J Clin Oncol"},{"key":"520_CR2","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","volume":"17","author":"SB Edge","year":"2010","unstructured":"Edge SB, Compton CC. The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471\u20134.","journal-title":"Ann Surg Oncol"},{"key":"520_CR3","doi-asserted-by":"publisher","unstructured":"Shaikh WR, Dusza SW, Weinstock MA, Oliveria SA, Geller AC, Halpern AC. Melanoma thickness and survival trends in the United States, 1989 to 2009. J Natl Cancer Inst. 2015; \n                    https:\/\/doi.org\/10.1093\/jnci\/djv294\n                    \n                  .","DOI":"10.1093\/jnci\/djv294"},{"key":"520_CR4","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1038\/jid.2014.452","volume":"135","author":"DC Whiteman","year":"2015","unstructured":"Whiteman DC, Baade PD, Olsen CM. More people die from thin melanomas (1 mm) than from thick melanomas (>4 mm) in Queensland. Aust J Invest Dermatol. 2015;135:1190\u20133.","journal-title":"Aust J Invest Dermatol"},{"key":"520_CR5","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1001\/jamadermatol.2016.4512","volume":"153","author":"AM Glazer","year":"2017","unstructured":"Glazer AM, Winkelmann RR, Farberg AS, Rigel DS. Analysis of trends in US melanoma incidence and mortality. JAMA Dermatol. 2017;153:225\u20136.","journal-title":"JAMA Dermatol"},{"key":"520_CR6","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780\u20138.","journal-title":"J Clin Oncol"},{"key":"520_CR7","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1245\/s10434-017-5771-0","volume":"24","author":"N Bhutiani","year":"2017","unstructured":"Bhutiani N, Egger ME, McMasters KM. Optimizing follow-up assessment of patients with Cutaneous melanoma. Ann Surg Oncol. 2017;24:861\u20133.","journal-title":"Ann Surg Oncol"},{"key":"520_CR8","doi-asserted-by":"publisher","unstructured":"Leon-Ferre RA, Kottschade LA, Block MS, McWilliams RR, Dronca RS, Creagan ET, et al. Association between the use of surveillance PET\/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma. Melanoma Res. 2017; doi:\n                    10.1097\/CMR.0000000000000344\n                    \n                  .","DOI":"10.1097\/CMR.0000000000000344"},{"key":"520_CR9","doi-asserted-by":"publisher","unstructured":"Nishino M, Giobbie-Hurder A, Ramaiya NH, Hodi FS. Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome. J Immunother Cancer. 2014; doi:\n                    10.1186\/s40425-014-0040-2\n                    \n                  .","DOI":"10.1186\/s40425-014-0040-2"},{"key":"520_CR10","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1245\/s10434-017-5768-8","volume":"24","author":"TS Park","year":"2017","unstructured":"Park TS, Phan GQ, Yang JC, Kammula U, Hughes MS, Trebska-McGowan K, et al. Routine computer tomography imaging for the detection of recurrences in high-risk melanoma patients. Ann Surg Oncol. 2017;24:947\u201351.","journal-title":"Ann Surg Oncol"},{"key":"520_CR11","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jaad.2016.02.1229","volume":"75","author":"S Podlipnik","year":"2016","unstructured":"Podlipnik S, Carrera C, Sanchez M, Arguis P, Olondo ML, Vilana R, et al. Performance of diagnostic tests in an intensive follow-up protocol for patients with American joint committee on cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: a prospective cohort study. J Am Acad Dermatol. 2016;75:516\u201324.","journal-title":"J Am Acad Dermatol"},{"key":"520_CR12","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1158\/1078-0432.CCR-13-3316","volume":"21","author":"P Gerami","year":"2015","unstructured":"Gerami P, Cook RW, Wilkinson J, Russell MC, Dhillon N, Amaria RN, et al. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin Cancer Res. 2015;21:175\u201383.","journal-title":"Clin Cancer Res"},{"key":"520_CR13","doi-asserted-by":"publisher","first-page":"461","DOI":"10.2353\/jmoldx.2010.090220","volume":"12","author":"MD Onken","year":"2010","unstructured":"Onken MD, Worley LA, Tuscan MD, Harbour JW. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn. 2010;12:461\u20138.","journal-title":"J Mol Diagn"},{"key":"520_CR14","doi-asserted-by":"publisher","first-page":"7205","DOI":"10.1158\/0008-5472.CAN-04-1750","volume":"64","author":"MD Onken","year":"2004","unstructured":"Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 2004;64:7205\u20139.","journal-title":"Cancer Res"},{"key":"520_CR15","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1158\/1078-0432.CCR-06-1820","volume":"13","author":"J Jaeger","year":"2007","unstructured":"Jaeger J, Koczan D, Thiesen HJ, Ibrahim SM, Gross G, Spang R, et al. Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin Cancer Res. 2007;13:806\u201315.","journal-title":"Clin Cancer Res"},{"key":"520_CR16","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/35020115","volume":"406","author":"M Bittner","year":"2000","unstructured":"Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature. 2000;406:536\u201340.","journal-title":"Nature"},{"key":"520_CR17","doi-asserted-by":"publisher","first-page":"6092","DOI":"10.1073\/pnas.0501564102","volume":"102","author":"C Haqq","year":"2005","unstructured":"Haqq C, Nosrati M, Sudilovsky D, Crothers J, Khodabakhsh D, Pulliam BL, et al. The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A. 2005;102:6092\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"520_CR18","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/j.1600-0625.2011.01254.x","volume":"20","author":"A Mauerer","year":"2011","unstructured":"Mauerer A, Roesch A, Hafner C, Stempfl T, Wild P, Meyer S, et al. Identification of new genes associated with melanoma. Exp Dermatol. 2011;20:502\u20137.","journal-title":"Exp Dermatol"},{"key":"520_CR19","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1002\/ijc.24899","volume":"126","author":"M Scatolini","year":"2010","unstructured":"Scatolini M, Grand MM, Grosso E, Venesio T, Pisacane A, Balsamo A, et al. Altered molecular pathways in melanocytic lesions. Int J Cancer. 2010;126:1869\u201381.","journal-title":"Int J Cancer"},{"key":"520_CR20","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.4161\/cbt.4.9.2165","volume":"4","author":"AP Smith","year":"2005","unstructured":"Smith AP, Hoek K, Becker D. Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi\/melanoma in situ and advanced-stage melanomas. Cancer Biol Ther. 2005;4:1018\u201329.","journal-title":"Cancer Biol Ther"},{"key":"520_CR21","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.jaad.2015.01.009","volume":"72","author":"P Gerami","year":"2015","unstructured":"Gerami P, Cook RW, Russell MC, Wilkinson J, Amaria RN, Gonzalez R, et al. Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. J Am Acad Dermatol. 2015;72:780\u20135. e3","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 15","key":"520_CR22","doi-asserted-by":"crossref","first-page":"9581","DOI":"10.1200\/JCO.2016.34.15_suppl.9581","volume":"34","author":"JS Zager","year":"2016","unstructured":"Zager JS, Gastman BR, Messina J, Sondak VK, Ferris L, Cook RW, et al. Performance of a 31-gene expression profile in a previously unreported cohort of 334 cutaneous melanoma patients. J Clin Oncol. 2016;34(Suppl 15):9581.","journal-title":"J Clin Oncol"},{"key":"520_CR23","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.amjsurg.2012.05.021","volume":"204","author":"AL Burton","year":"2012","unstructured":"Burton AL, Egger ME, Gilbert JE, Stromberg AJ, Hagendoorn L, Martin RC, et al. Assessment of mitotic rate reporting in melanoma. Am J Surg. 2012;204:969\u201375.","journal-title":"Am J Surg"},{"key":"520_CR24","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa1310460","volume":"370","author":"DL Morton","year":"2014","unstructured":"Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Nieweg OE, Roses DF, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370:599\u2013609.","journal-title":"N Engl J Med"},{"key":"520_CR25","doi-asserted-by":"publisher","first-page":"450","DOI":"10.6004\/jnccn.2016.0051","volume":"14","author":"DG Coit","year":"2016","unstructured":"Coit DG, Thompson JA, Algazi A, Andtbacka R, Bichakjian CK, Carson WE 3rd, et al. Melanoma, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2016;14:450\u201373.","journal-title":"J Natl Compr Cancer Netw"},{"key":"520_CR26","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1016\/j.ophtha.2012.02.017","volume":"119","author":"MD Onken","year":"2012","unstructured":"Onken MD, Worley LA, Char DH, Augsburger JJ, Correa ZM, Nudleman E, et al. Collaborative ocular oncology group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology. 2012;119:1596\u2013603.","journal-title":"Ophthalmology"},{"key":"520_CR27","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1056\/NEJMoa021967","volume":"347","author":"MJ Vijver van de","year":"2002","unstructured":"van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999\u20132009.","journal-title":"N Engl J Med"},{"issue":"Suppl 15","key":"520_CR28","doi-asserted-by":"crossref","first-page":"9074","DOI":"10.1200\/jco.2015.33.15_suppl.9074","volume":"33","author":"H Kaufman","year":"2015","unstructured":"Kaufman H, Amatruda T, Nemunaitis JJ, Chesne JA, Delman KA, Spitler LE, et al. Tumor size and clinical outcomes in melanoma patients (MEL pts) treated with talimogene laherparepvec (T-VEC). J Clin Oncol. 2015;33(Suppl 15):9074.","journal-title":"J Clin Oncol"},{"key":"520_CR29","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1001\/jama.2016.4059","volume":"315","author":"A Ribas","year":"2016","unstructured":"Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA. 2016;315:1600\u20139.","journal-title":"JAMA"}],"updated-by":[{"DOI":"10.1186\/s13045-017-0524-x","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T00:00:00Z","timestamp":1507161600000}}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-017-0520-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13045-017-0520-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-017-0520-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T18:58:46Z","timestamp":1581965926000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-017-0520-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,29]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["520"],"URL":"https:\/\/doi.org\/10.1186\/s13045-017-0520-1","relation":{"erratum":[{"id-type":"doi","id":"10.1186\/s13045-017-0524-x","asserted-by":"object"}]},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,29]]},"assertion":[{"value":"23 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2017","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Erratum","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An erratum to this article has been published.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The current study was approved by the following Institutional Review Boards:Written informed patient consent was obtained from study participants before enrollment in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ECH and JJS are on Castle Biosciences\u2019 Speaker Bureau. ECH, JJS, JL, and CLS have received honoraria for advisory board participation. KRC, BM, CJ, and RWC are employees of Castle Biosciences, Inc. and hold stock in the company. All remaining authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"152"}}